GSK1614343 | 1092076-04-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 英文名称: GSK1614343
• 英文别名: (2R)-N'-[3,5-bis(trifluoromethyl)phenyl]-2-[(8aR)-hexahydropyrrolo[1,2-a]pyrazin-2(1H)-yl]-2-(3-pyridinyl)ethanohydrazide；(2R)-N'-[3,5-bis(trifluoromethyl)phenyl]-2-[(8aR)-hexahydropyrrolo[1,2-a]pyrazin-2(1H)-yl]-2-(3-pyridinyl)acetohydrazide；(2R)-2-[(8aR)-3,4,6,7,8,8a-hexahydro-1H-pyrrolo[1,2-a]pyrazin-2-yl]-N'-[3,5-bis(trifluoromethyl)phenyl]-2-pyridin-3-ylacetohydrazide
• CAS: 1092076-04-4
• 化学式: C₂₂H₂₃F₆N₅O
• 分子量: 487.448
• InChiKey: QNOSCJDGJKVFJR-RTBURBONSA-N

物化性质

• 沸点：
  485.9±45.0 °C(Predicted)
• 密度：
  1.43±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  4.2
• 重原子数：
  34
• 可旋转键数：
  5
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.45
• 拓扑面积：
  60.5
• 氢给体数：
  2
• 氢受体数：
  11

反应信息

• 作为反应物：
  描述：

  GSK1614343 在 盐酸 作用下， 以 甲醇 、 乙醚 为溶剂， 反应 0.08h， 以100%的产率得到GSK1614343 hydrochloride
  参考文献：
  名称：

  WO2008/148853

  摘要：

  公开号：
• 作为产物：
  描述：

  N'-[3,5-bis(trifluoromethyl)phenyl]-2-[(8aR)-hexahydropyrrolo[1,2-a]pyrazin-2(1H)-yl]-2-(3-pyridinyl)acetohydrazide 以 乙醇 为溶剂， 以to give the title compound as a yellow solid (285 mg, 42%)的产率得到GSK1614343
  参考文献：
  名称：

  N-PHENYL HYDRAZIDES AS MODULATORS OF THE GHRELIN RECEPTOR

  摘要：

  本发明涉及公式（I）的新化合物或其药学上可接受的盐或溶剂。

  公开号：

  US20100286152A1

文献信息

• WO2008/148854
  申请人：——

  公开号：——

  公开（公告）日：——
• [EN] N-PHENYL HYDRAZIDES AS MODULATORS OF THE GHRELIN RECEPTOR<br/>[FR] HYDRAZIDES N-PHÉNYLE COMME MODULATEURS DU RÉCEPTEUR DE LA GRÉHLINE
  申请人：GLAXO GROUP LTD

  公开号：WO2008148853A1

  公开（公告）日：2008-12-11

  [EN] The present invention relates to novel compounds of formula (I) or a pharmaceutically acceptable salt or solvate thereof, wherein: each R1 is independently selected from the group consisting of Cl, Br, CH3 and CF3; X is carbon or nitrogen; R1a is H or a straight C1-3 alkyl group; R2a is H or a methyl group R2 is selected from the group consisting of C1-3alkyl, H and -(CH2)n-, wherein n is 3 or 4 and the terminal carbon of the chain is bonded to the carbon atom adjacent to the nitrogen bearing the R2 group, such that a fused 6,5 or 6,6-bicyclic ring is formed. Y is selected from the group consisting of: phenyl which may be unsubstituted or substituted by one or more substituents independently selected from the group consisting of C1-3alkyl, C1-3alkoxy, halogen, C1-3alkyl substituted by 1 to 7 fluoro atoms and C1-3alkoxy substituted by 1 to 7 fluoro atoms; pyridyl which may be unsubstituted or substituted by one or more substituents independently selected from the group consisting of C1-3alkyl, OCH3, CF3, CN, and halogen; naphthyl which may be unsubstituted or substituted by one or more substituents independently selected from the group consisting of F and OCH3; pyrimidinyl; imidazo[1,2-a]pyridine-6-yl; benzothiophen-2-yl; benzothiophen-5-yl; benzofuran-2-yl; dibenzo[b,d]furan-3-yl; dibenzo[b,d]thiophen-2-yl; dibenzo[b,d]thiophen-4-yl; 1,3- benzodioxol-5-yl; 2,3-dihydro-1,4-benzodioxin-5-yl; 2,3-dihydro-1,4-benzodioxin-6-yl; 2,3- dihydro-1-benzofuran-4-yl; 2,2-difluoro-1,3-benzodiox-4-yl; pyridazinyl; imidazolyl; oxazolyl; pyrazolyl; thiazolyl; and triazolyl; with the proviso that when Y is 2,3-dihydro-1,4-benzodioxin-6-yl, R1 is not Cl; processes for their preparation, intermediates useble in these processes, pharmaceutical compositions containing them and their use in therapy, for example as modulators of of the growth hormone secretagogue receptor (also referred to as the ghrelin receptor or GHSR1a receptor) and/or for the treatment and/or prophylaxis of a disorder mediated by the ghrelin receptor.
  [FR] L'invention concerne de nouveaux composés de formule (I) ou un sel ou un solvate pharmaceutiquement acceptable de ceux-ci, dans laquelle R1 est indépendamment sélectionné dans le groupe formé de Cl, Br, CH3 et CF3; X représente carbone ou azote; R1a représente H ou un groupe alkyle C1-3 linéaire; R2a représente H ou un groupe méthyle R2 est sélectionné dans le groupe formé d'alkyle C1-3,
• [EN] GHRELIN MODULATORS<br/>[FR] MODULATEURS DE LA GHRÉLINE
  申请人：GLAXO GROUP LTD

  公开号：WO2008148854A1

  公开（公告）日：2008-12-11

  [EN] The present invention relates to novel compounds of formula (I) or a pharmaceutically acceptable salt or solvate thereof, processes for their preparation, intermediates useble in these processes, pharmaceutical compositions containing them and their use in therapy, for example as modulators of of the growth hormone secretagogue receptor (also referred to as the ghrelin receptor or GHSR1a receptor) and/or for the treatment and/or prophylaxis of a disorder mediated by the ghrelin receptor.
  [FR] L'invention concerne de nouveaux composés de formule (I) ou un sel ou un solvate pharmaceutiquement acceptable, leurs procédés de préparation, les intermédiaires pouvant servir dans ces procédés, des compositions pharmaceutiques les contenant et leur utilisation en thérapie, par exemple comme modulateurs du récepteur des sécrétagogues de l'hormone de croissance (également appelé récepteur de la ghréline ou récepteur GHSR1a) et/ou pour le traitement et/ou la prophylaxie d'un trouble médié par le récepteur de la ghréline.
• WO2008/148853
  申请人：——

  公开号：——

  公开（公告）日：——
• N-PHENYL HYDRAZIDES AS MODULATORS OF THE GHRELIN RECEPTOR
  申请人：Bernasconi Giovanni

  公开号：US20100286152A1

  公开（公告）日：2010-11-11

  The present invention relates to novel compounds of formula (I) or a pharmaceutically acceptable salt or solvate thereof,

  本发明涉及公式（I）的新化合物或其药学上可接受的盐或溶剂。